Recap: ChemoCentryx Q3 Earnings

Shares of ChemoCentryx CCXI fell 8.59% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were down 59.09% year over year to ($0.35), which missed the estimate of ($0.31).

Revenue of $5,085,000 declined by 51.94% from the same period last year, which missed the estimate of $10,700,000.

Guidance

ChemoCentryx hasn't issued any earnings guidance for the time being.

ChemoCentryx hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Nov 09, 2020

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/ehp3weoi

Price Action

Company's 52-week high was at $65.43

Company's 52-week low was at $7.88

Price action over last quarter: Up 8.05%

Company Description

ChemoCentryx Inc is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.